Abstract
Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is one of the most frequently disrupted tumor suppressors in cancer. The lipid phosphatase activity of PTEN antagonizes the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway to repress tumor cell growth and survival. In the nucleus, PTEN promotes chromosome stability and DNA repair. Consequently, loss of PTEN function increases genomic instability. PTEN deficiency is caused by inherited germline mutations, somatic mutations, epigenetic and transcriptional silencing, post-translational modifications, and protein-protein interactions. Given the high frequency of PTEN deficiency across cancer subtypes, therapeutic approaches that exploit PTEN loss-of-function could provide effective treatment strategies. Herein, we discuss therapeutic strategies aimed at cancers with loss of PTEN function, and the challenges involved in treating patients afflicted with such cancers. We review preclinical and clinical findings, and highlight novel strategies under development to target PTENdeficient cancers.
Keywords: Cancer, phosphatase, targeted therapy, tumor, tumor suppressor, PI3K, mTOR, synthetic lethal.
Current Drug Targets
Title:Therapeutic Targeting of Cancers with Loss of PTEN Function
Volume: 15 Issue: 1
Author(s): Lloye M. Dillon and Todd W. Miller
Affiliation:
Keywords: Cancer, phosphatase, targeted therapy, tumor, tumor suppressor, PI3K, mTOR, synthetic lethal.
Abstract: Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is one of the most frequently disrupted tumor suppressors in cancer. The lipid phosphatase activity of PTEN antagonizes the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway to repress tumor cell growth and survival. In the nucleus, PTEN promotes chromosome stability and DNA repair. Consequently, loss of PTEN function increases genomic instability. PTEN deficiency is caused by inherited germline mutations, somatic mutations, epigenetic and transcriptional silencing, post-translational modifications, and protein-protein interactions. Given the high frequency of PTEN deficiency across cancer subtypes, therapeutic approaches that exploit PTEN loss-of-function could provide effective treatment strategies. Herein, we discuss therapeutic strategies aimed at cancers with loss of PTEN function, and the challenges involved in treating patients afflicted with such cancers. We review preclinical and clinical findings, and highlight novel strategies under development to target PTENdeficient cancers.
Export Options
About this article
Cite this article as:
Dillon M. Lloye and Miller W. Todd, Therapeutic Targeting of Cancers with Loss of PTEN Function, Current Drug Targets 2014; 15 (1) . https://dx.doi.org/10.2174/1389450114666140106100909
DOI https://dx.doi.org/10.2174/1389450114666140106100909 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Amygdalin from Apricot Kernels Induces Apoptosis and Causes Cell Cycle Arrest in Cancer Cells: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry A Review on Synthetic and Natural Steroid Dimers: 1997-2006
Current Medicinal Chemistry Radionuclide Molecular Imaging Using Affibody Molecules
Current Pharmaceutical Biotechnology Juglone Exerts Cytotoxic, Anti-proliferative and Anti-invasive Effects on Glioblastoma Multiforme in a Cell Culture Model
Anti-Cancer Agents in Medicinal Chemistry The Therapeutic Value of Natural Agents to Treat miRNA Targeted Breast Cancer in African-American and Caucasian-American Women
Current Drug Targets Sesamol: An Efficient Antioxidant with Potential Therapeutic Benefits
Medicinal Chemistry Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
Current Medicinal Chemistry Phytochemical and Biological Activities of an Anticancer Plant Medicine: Brucea javanica
Anti-Cancer Agents in Medicinal Chemistry Biotransformation of Silybin and its Congeners
Current Drug Metabolism The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design Molecular and Cellular Mechanisms of Hexavalent Chromium-Induced Lung Cancer: An Updated Perspective
Current Drug Metabolism Pharmacokinetic Profiles of Anticancer Herbal Medicines in Humans and the Clinical Implications
Current Medicinal Chemistry Weekly Low-doses with Prolonged Infusion of Gemcitabine /Cisplatin for Multi-treated Metastatic Breast Cancer Patients
Current Cancer Therapy Reviews Hydrogen Sulfide Regulates Intracellular Ca2+ Concentration in Endothelial Cells From Excised Rat Aorta
Current Pharmaceutical Biotechnology The Current Status of Cryotherapy and High-Intensity Focused UltraSound in the Treatment of Low-Grade Prostate Cancer
Reviews on Recent Clinical Trials Radiolabeled Nanoparticles for Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as Drivers of Oncogenesis and Potential Drug Targets
Current Cancer Drug Targets The Role of Mitochondria in Cancer Induction, Progression and Changes in Metabolism
Mini-Reviews in Medicinal Chemistry MIIP, a Cytoskeleton Regulator that Blocks Cell Migration and Invasion, Delays Mitosis, and Suppresses Tumorogenesis
Current Protein & Peptide Science